| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Secukinumab |
| Brand | Cosentyx® |
| Indication | For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 19/12/2014 |
| Rapid review completed | 05/02/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 02/04/2015 |
| NCPE assessment completed | 16/09/2015 |
| NCPE assessment outcome | Reimbursement Not Recommended at the Submitted Price. |
The HSE has approved reimbursement following confidential price negotiations December 2015.
